Conquest - Fall 2013
A drug. A disease. Three studies. Four investigators.
Analyzing bevacizumab for glioblastomas
By Laura Sussman, William Fitzgerald and Sandi Stromberg
Glioblastoma remains the most common and lethal of brain cancers. So it isn’t surprising that when a drug shows early promise, MD Anderson clinical researchers design protocols to understand how effective it will be for patients — especially in a disease that has too few effective treatments.
At the 2013 annual meeting of the American Society of Clinical Oncology (ASCO), four investigators presented their findings in studies with bevacizumab (Avastin) for patients newly diagnosed with glioblastoma.
The drug, which blocks blood vessel growth that feeds the tumor, first showed promise in patients when clinicians reported positive results treating the disease under approved compassionate use. Numerous studies then found similar results: 35% to 40% tumor shrinkage in more than 50% of the patients — with a 50% progression-free survival rate in 30% of them. With these findings in May 2009, the U.S. Food and Drug Administration granted accelerated registration of bevacizumab for recurrent, re-growing glioblastoma.
- STUDY NO.1: Bevacizumab fails newly diagnosed glioblastoma patients
- STUDY NO.2: Diagnostic tool may help predict right patients for bevacizumab
- STUDY NO.3: Bevacizumab reduces cognitive function and quality of life
In This Issue
- No. 1 again for MD Anderson
- Where you live may raise your risk of obesity
- Abbott acquires MD Anderson technology company
- Check out Conquest on your iPad
Signs of hope: